US Liquid Biopsy Market (By Biomarker Types: Circulating Tumor Cells (CTCs), Circulating Tumor DNA (CTDNA), Extracellular Vesicles (EVS), Other Biomarkers; By Application: Cancer Therapeutic Application, Reproductive Health, Other Therapeutic Application; By Sample: Blood Sample, Urine Sample, other; By End User: Hospitals and Laboratories, Academic and Research Centers, other End Users) - Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2032

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on US Liquid Biopsy Market 

5.1. COVID-19 Landscape: US Liquid Biopsy Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. US Liquid Biopsy Market, By Biomarker Types

8.1. US Liquid Biopsy Market, by Biomarker Types, 2022-2032

8.1.1. Circulating Tumor Cells (CTCs)

8.1.1.1. Market Revenue and Forecast (2022-2032)

8.1.2. Circulating Tumor DNA (CTDNA)

8.1.2.1. Market Revenue and Forecast (2022-2032)

8.1.3. Extracellular vesicles (EVS)

8.1.3.1. Market Revenue and Forecast (2022-2032)

8.1.4. Other Biomarkers

8.1.4.1. Market Revenue and Forecast (2022-2032)

Chapter 9. US Liquid Biopsy Market, By Application

9.1. US Liquid Biopsy Market, by Application, 2022-2032

9.1.1. Cancer Therapeutic Application

9.1.1.1. Market Revenue and Forecast (2022-2032)

9.1.2. Reproductive Health

9.1.2.1. Market Revenue and Forecast (2022-2032)

9.1.3. Other Therapeutic Application

9.1.3.1. Market Revenue and Forecast (2022-2032)

Chapter 10. US Liquid Biopsy Market, By Sample 

10.1. US Liquid Biopsy Market, by Sample, 2022-2032

10.1.1. Blood Sample

10.1.1.1. Market Revenue and Forecast (2022-2032)

10.1.2. Urine Sample

10.1.2.1. Market Revenue and Forecast (2022-2032)

10.1.3. Other

10.1.3.1. Market Revenue and Forecast (2022-2032)

Chapter 11. US Liquid Biopsy Market, By End User 

11.1. US Liquid Biopsy Market, by End User, 2022-2032

11.1.1. Hospitals and Laboratories

11.1.1.1. Market Revenue and Forecast (2022-2032)

11.1.2. Academic and Research Centers

11.1.2.1. Market Revenue and Forecast (2022-2032)

11.1.3. Other End Users

11.1.3.1. Market Revenue and Forecast (2022-2032)

Chapter 12. US Liquid Biopsy Market, Regional Estimates and Trend Forecast

12.1. U.S.

12.1.1. Market Revenue and Forecast, by Biomarker Types (2022-2032)

12.1.2. Market Revenue and Forecast, by Application (2022-2032)

12.1.3. Market Revenue and Forecast, by Sample (2022-2032)

12.1.4. Market Revenue and Forecast, by End User (2022-2032)

Chapter 13. Company Profiles

13.1. ANGLE plc, Biocept Inc.

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Bio-Rad Laboratories Inc.

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Epigenomics AG

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Exact Sciences Corporation

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. F. Hoffmann-La Roche AG

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Guardant Health Inc.

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Illumina Inc.

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. MDxHealth SA

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Menarini Silicon Biosystems

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. QIAGEN N.V.

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

PROCEED TO BUY :

   USD 4900
   USD 3800
   USD 1900
   USD 1200

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client

Get a Sample